142 related articles for article (PubMed ID: 38243715)
1. Effectiveness of Sequential Lines of Biologic and Targeted Small Molecule Drugs in Psoriatic Arthritis: A Systematic Review.
Gollins CE; Vincent R; Fahy C; McHugh N; Brooke M; Tillett W
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38243715
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of sequential lines of biologic and targeted small molecule drugs in psoriasis: A systematic review and meta-analysis.
Gollins CE; Vincent R; Fahy C; McHugh N; Tillett W
Skin Health Dis; 2024 Apr; 4(2):e350. PubMed ID: 38577060
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
5. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
[TBL] [Abstract][Full Text] [Related]
6. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
7. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
[TBL] [Abstract][Full Text] [Related]
8. The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register.
Jones GT; Macfarlane GJ; Forrest Keenan K; McNamee P; Neilson AR; Siebert S; Burden AD; Kay L; Helliwell PS
BMC Rheumatol; 2021 May; 5(1):19. PubMed ID: 33993880
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
[No Abstract] [Full Text] [Related]
10. Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.
Reddy SM; Crean S; Martin AL; Burns MD; Palmer JB
Clin Rheumatol; 2016 Dec; 35(12):2955-2966. PubMed ID: 27730309
[TBL] [Abstract][Full Text] [Related]
11. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis.
Vassilopoulos A; Shehadeh F; Benitez G; Kalligeros M; Cunha JS; Cunha CB; Mylonakis E
Front Pharmacol; 2022; 13():992713. PubMed ID: 36278224
[No Abstract] [Full Text] [Related]
12. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
13. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study.
Benavent D; Muñoz-Fernández S; De la Morena I; Fernández-Nebro A; Marín-Corral J; Castillo Rosa E; Taberna M; Sanabra C; Sastre C;
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231220818. PubMed ID: 38146537
[TBL] [Abstract][Full Text] [Related]
14. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review.
Sparks JA; Harrold LR; Simon TA; Wittstock K; Kelly S; Lozenski K; Khaychuk V; Michaud K
Semin Arthritis Rheum; 2023 Oct; 62():152249. PubMed ID: 37573754
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
17. Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Chakravarty SD; McLean RR; Blachley T; Kawashima T; Lin I; Kavanaugh A; Ogdie A
ACR Open Rheumatol; 2022 May; 4(5):447-456. PubMed ID: 35218320
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
Nguyen H; Ahmed K; Luo W; Flint J; Giles I
Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
